Literature DB >> 10733487

Transformation of mycosis fungoides: clinicopathological and prognostic features of 45 cases. French Study Group of Cutaneious Lymphomas.

B Vergier1, A de Muret, M Beylot-Barry, L Vaillant, D Ekouevi, G Chene, A Carlotti, N Franck, P Dechelotte, P Souteyrand, P Courville, P Joly, M Delaunay, M Bagot, F Grange, S Fraitag, J Bosq, T Petrella, A Durlach, A De Mascarel, J P Merlio, J Wechsler.   

Abstract

The course of mycosis fungoides (MF) is indolent except when transformation to a large T-cell lymphoma occurs. The diagnosis of transformed MF (T-MF) relies on the presence of more than 25% of large cells on biopsy of an MF lesion. We analyzed 45 patients with T-MF recorded by the French Study Group on Cutaneous Lymphomas to better determine clinicopathological features of MF transformation and to analyze their impact on prognosis. Median time from diagnosis of MF to transformation was 6.5 years. Extracutaneous progression was present in 20 patients. Mean survival from transformation to death was 22 months. In univariate analysis, only an extracutaneous progression was associated with a worse prognosis (5-year actuarial survival: 7.8% versus 32%). Neither sex, age, clinical and skin disease stage at transformation, transformation speed, nor percentage of large cells or CD30 expression (14 of 45) had a prognostic value. When performing multivariate analysis, age (at least 60 years), and extracutaneous spreading were found to be associated with a poor prognosis. There was no difference between survival curves of patients with T-MF and with pleomorphic large T-cell CD30- lymphomas. The main diagnostic pitfall was "histiocytic-rich" MF, requiring CD68 staining for the diagnosis of T-MF. Out of 45 patients, 6 presented an histologic transformation before clinical progression, suggesting that an early histopathological diagnosis may be performed by histological follow-up. The prognostic value of such early histopathological diagnosis must be confirmed by prospective studies.

Entities:  

Mesh:

Year:  2000        PMID: 10733487

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  37 in total

1.  Mycosis fungoides with large cell transformation: clinicopathological features and prognostic factors.

Authors:  Melissa Pulitzer; Patricia L Myskowski; Steven M Horwitz; Christiane Querfeld; Brian Connolly; Janet Li; Rajmohan Murali
Journal:  Pathology       Date:  2014-12       Impact factor: 5.306

2.  Mycosis fungoides and CD30+ cutaneous T-cell lymphoma simulating pyoderma gangrenosum in a patient with ulcerative colitis.

Authors:  Fares Salameh; Aviv Barzilai; Sharon Baum; Henri Trau
Journal:  J Dermatol Case Rep       Date:  2009-08-24

3.  Nodal involvement by cutaneous CD30-positive T-cell lymphoma mimicking classical Hodgkin lymphoma.

Authors:  Franziska C Eberle; Joo Y Song; Liqiang Xi; Mark Raffeld; Nancy Lee Harris; Wyndham H Wilson; Stefania Pittaluga; Elaine S Jaffe
Journal:  Am J Surg Pathol       Date:  2012-05       Impact factor: 6.394

Review 4.  The current management of mycosis fungoides and Sézary syndrome and the role of radiotherapy: Principles and indications.

Authors:  Ercole Mazzeo; Laura Rubino; Michela Buglione; Paolo Antognoni; Stefano Maria Magrini; Francesco Bertoni; Manuela Parmiggiani; Paola Barbieri; Filippo Bertoni
Journal:  Rep Pract Oncol Radiother       Date:  2013-08-13

5.  Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model.

Authors:  Julia J Scarisbrick; H Miles Prince; Maarten H Vermeer; Pietro Quaglino; Steven Horwitz; Pierluigi Porcu; Rudolf Stadler; Gary S Wood; Marie Beylot-Barry; Anne Pham-Ledard; Francine Foss; Michael Girardi; Martine Bagot; Laurence Michel; Maxime Battistella; Joan Guitart; Timothy M Kuzel; Maria Estela Martinez-Escala; Teresa Estrach; Evangelia Papadavid; Christina Antoniou; Dimitis Rigopoulos; Vassilki Nikolaou; Makoto Sugaya; Tomomitsu Miyagaki; Robert Gniadecki; José Antonio Sanches; Jade Cury-Martins; Denis Miyashiro; Octavio Servitje; Cristina Muniesa; Emilio Berti; Francesco Onida; Laura Corti; Emilia Hodak; Iris Amitay-Laish; Pablo L Ortiz-Romero; Jose L Rodríguez-Peralto; Robert Knobler; Stefanie Porkert; Wolfgang Bauer; Nicola Pimpinelli; Vieri Grandi; Richard Cowan; Alain Rook; Ellen Kim; Alessandro Pileri; Annalisa Patrizi; Ramon M Pujol; Henry Wong; Kelly Tyler; Rene Stranzenbach; Christiane Querfeld; Paolo Fava; Milena Maule; Rein Willemze; Felicity Evison; Stephen Morris; Robert Twigger; Rakhshandra Talpur; Jinah Kim; Grant Ognibene; Shufeng Li; Mahkam Tavallaee; Richard T Hoppe; Madeleine Duvic; Sean J Whittaker; Youn H Kim
Journal:  J Clin Oncol       Date:  2015-10-05       Impact factor: 44.544

6.  In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study.

Authors:  Youn H Kim; Dita Gratzinger; Cameron Harrison; Joshua D Brody; Debra K Czerwinski; Weiyun Z Ai; Anjali Morales; Farah Abdulla; Leon Xing; Daniel Navi; Robert J Tibshirani; Ranjana H Advani; Bharathi Lingala; Sumit Shah; Richard T Hoppe; Ronald Levy
Journal:  Blood       Date:  2011-11-01       Impact factor: 22.113

7.  Allogeneic stem cell transplantation for advanced cutaneous T-cell lymphomas: a study from the French Society of Bone Marrow Transplantation and French Study Group on Cutaneous Lymphomas.

Authors:  Adèle de Masson; Marie Beylot-Barry; Jean-David Bouaziz; Régis Peffault de Latour; François Aubin; Sylvain Garciaz; Michel d'Incan; Olivier Dereure; Stéphane Dalle; Anne Dompmartin; Felipe Suarez; Maxime Battistella; Marie-Dominique Vignon-Pennamen; Jacqueline Rivet; Henri Adamski; Pauline Brice; Sylvie François; Séverine Lissandre; Pascal Turlure; Ewa Wierzbicka-Hainaut; Eolia Brissot; Rémy Dulery; Sophie Servais; Aurélie Ravinet; Reza Tabrizi; Saskia Ingen-Housz-Oro; Pascal Joly; Gérard Socié; Martine Bagot
Journal:  Haematologica       Date:  2013-11-08       Impact factor: 9.941

Review 8.  Central nervous system prophylaxis in non-Hodgkin lymphoma: who, what, and when?

Authors:  Chan Yoon Cheah; John F Seymour
Journal:  Curr Oncol Rep       Date:  2015-06       Impact factor: 5.075

Review 9.  Receptor-directed therapy of T-cell leukemias and lymphomas.

Authors:  John C Morris; Thomas A Waldmann; John E Janik
Journal:  J Immunotoxicol       Date:  2008-04       Impact factor: 3.000

10.  CD30+ Large Cell Transformation of Mycosis Fungoides During Pregnancy.

Authors:  Farahnaz Fatemi Naeini; Jamshid Najafian; Mohammadali Nilforoushzadeh
Journal:  Indian J Dermatol       Date:  2013-03       Impact factor: 1.494

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.